{"id":170225,"date":"2025-08-15T07:44:28","date_gmt":"2025-08-15T11:44:28","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170225"},"modified":"2025-08-15T07:44:28","modified_gmt":"2025-08-15T11:44:28","slug":"supriya-lifescience-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/supriya-lifescience-q1-fy26-earnings-results\/","title":{"rendered":"Supriya Lifescience Q1 FY26 Earnings Results\u00a0"},"content":{"rendered":"<p>Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Syntec Do Brasil LTDA, American International Chemical Inc. and AT Planejamento E Desenvolvimento De Negocios Ltd., Suan Farma Inc. Acme Generics LLP, Akum Drugs Ltd, and Mankind Pharma, among others. ~45% of their FY23 revenues were derived from its 10 largest customers. The Company has a manufacturing facility in Parshuram Lote, Maharashtra, with 5 manufacturing Blocks. It commissioned a new Module E Production Block, which increased the company&#8217;s capacity by over 55%, from 597 KLPD to 932 KLPD. Presenting below are its Q1 FY26 earnings results.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q1-fy26-earnings-summary-apriljune-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q1 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue:<\/strong> \u20b9145.07 crore, down 9.9% year-over-year (YoY) from \u20b9160.63 crore.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EBITDA:<\/strong>\u00a0\u20b951.7 crore, with EBITDA margin of 35.6% compared to 38.9% in Q1 FY25.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Profit After Tax (PAT):<\/strong>\u00a0\u20b934.79 crore, down from \u20b944.64 crore in Q1 FY25.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>PAT Margin:<\/strong>\u00a024.0% for Q1 FY26, down from 27.8% in Q1 FY25.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EPS:<\/strong>\u00a0\u20b94.3 compared with \u20b95.5 a year ago.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Segment Performance:<\/strong>\u00a0Anaesthetic segment led revenue growth, contributing 53% of revenue (up from 45% in Q1 FY25).<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Geography:<\/strong>\u00a0European markets contributed 41% to revenue, up from 34% YoY.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Capacity Utilization:<\/strong>\u00a0Improved to 76% in FY26 from 70% in FY25.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company has acquired three land parcels for future growth near various plants.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3 id=\"management-commentary--strategic-highlights\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Management Commentary &amp; Strategic Highlights<\/h3>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Production delays due to essential repair and maintenance at Lote facility <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/8d428a80-9f64-46c6-89ac-a37801df9724.pdf\" target=\"_blank\" rel=\"noopener\">impacted revenue<\/a>.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Upgrades aimed to improve efficiency and enable full utilization of new production modules for upcoming launches.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Despite <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/8d428a80-9f64-46c6-89ac-a37801df9724.pdf\" target=\"_blank\" rel=\"noopener\">revenue dip, margins remain strong<\/a>, supported by improved backward integration and increased regulatory market contribution.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Ambernath site is progressing towards commercial production.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management is confident in a return to growth trajectory and margin expansion for the full fiscal year.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company maintains a target of 20%+ revenue growth for FY26.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-170226\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10-839x1024.png\" alt=\"Supriya Lifescience Q1 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q4-fy25-earnings-snapshot-janmar-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q4 FY25 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue:<\/strong> \u20b9184.11 crore, up by 16.4 percent on the YoY basis.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EBITDA:<\/strong>\u00a0\u20b967.58 crore, with 36.7% margin.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>PAT:<\/strong> \u20b950.38 crore, up by 35% during the same period, last year.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>PAT Margin:<\/strong> 24.14%.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The quarter had strong operational performance and margin expansion compared to Q1 FY26.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>To view the company&#8217;s previous earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/supriya\/\">click here<\/a>\u00a0 to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Syntec Do Brasil LTDA, American International Chemical Inc. and AT Planejamento E Desenvolvimento De Negocios Ltd., Suan Farma Inc. [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":170226,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[11776],"class_list":["post-170225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-active-pharmaceutical-ingredients"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":164722,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits-2\/","url_meta":{"origin":170225,"position":0},"title":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits","author":"Chirag Gupta","date":"October 7, 2024","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151121,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits\/","url_meta":{"origin":170225,"position":1},"title":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits","author":"Chirag Gupta","date":"August 3, 2023","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":155892,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q2fy24-41-rise-in-profits\/","url_meta":{"origin":170225,"position":2},"title":"Supriya Lifescience Ltd Q2FY24; 41% rise in Profits","author":"Chirag Gupta","date":"November 7, 2023","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q2FY24 of \u20b9140.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180290,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-reports-11-2-revenue-growth-in-q3-fy26-driven-by-anesthetic-segment-and-export-demand\/","url_meta":{"origin":170225,"position":3},"title":"Supriya Lifescience Reports 11.2% Revenue Growth in Q3 FY26 Driven by Anesthetic Segment and Export Demand","author":"Staff Correspondent","date":"February 10, 2026","format":false,"excerpt":"Supriya Lifescience Limited (NSE: SUPRIYA) the active pharmaceutical ingredient manufacturer recorded increased top-line performance supported by higher capacity utilization and growth in regulated markets. While margins saw a slight year-over-year contraction, the company is moving toward the commissioning of its new formulation facility in the fourth quarter. Company reported a\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129979,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":170225,"position":4},"title":"Supriya Lifescience Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/VIL70Aj2g04 Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q4 FY22 Earnings Concall Management Update: SUPRIYA said that going forward the company\u2019s focus would be on improving its infrastructure, which includes debottlenecking of its capacity and developing new manufacturing blocks. Q&A Highlights: Naresh Vaswani of Sameeksha Capital asked about the reason\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133424,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":170225,"position":5},"title":"Supriya Lifescience Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 23, 2022","format":false,"excerpt":"https:\/\/youtu.be\/LNBcyeiXX0U Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q1 FY23 Earnings Concall Management Update: SUPRIYA said the company is extending its backward integration model to its new products to maintain the competitive edge. The company added that a larger part of the growth and sustainability will be driven by the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170225"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170226"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}